NCT04464122View on ClinicalTrials.gov

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

September 14, 2025

Study Completion Date

December 31, 2025

Conditions
Neuroendocrine TumorsNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Carcinoma
Interventions
DRUG

Somatostatin analog; chemotherapy

According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.

Trial Locations (1)

00161

RECRUITING

Andrea M Isidori, Rome

All Listed Sponsors
lead

University of Roma La Sapienza

OTHER